Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Azzolini, Michele (2015) Pharmacology of natural polyphenols: prodrugs and biochemistry of Resveratrol and Pterostilbene. [Tesi di dottorato]

Full text disponibile come:

[img]Documento PDF - Versione sottomessa
Tesi non accessible fino a 27 Gennaio 2018 per motivi correlati alla proprietà intellettuale.
Visibile a: nessuno


Abstract (inglese)

This thesis deals with aspects of the pharmacology of two polyphenols: Resveratrol and Pterostilbene.
These plant-made molecules are the object of intensive research due to their biological and biomedical activities, of interest in the context of various pathologies related to age, inflammation, neurodegeneration, cancer, obesity and diabetes. However, the mechanisms underlying the activity of Resveratrol, and in particular of Pterostilbene, are not completely known. Moreover, the presence of free hydroxyl group(s) (the common feature of polyphenols) renders both molecules good substrates for enzymes of phase II metabolism, whose activity strongly limits the bioavailability and the pharmacological exploitation of polyphenols.
During my graduate studies I have worked on both these themes. I will describe first what has been done to increase the bioavailability of both molecules. Second, I will summarize my ongoing investigation of the molecular mechanisms accounting for the activity of Pterostilbene and Resveratrol.
The strategy adopted by my research group to improve the efficacy of these polyphenols, viewed more as pharmaceuticals than as nutrients, involves the use of prodrugs. Prodrugs are essentially protected versions of a given molecule. Resveratrol in particular presents three main sites that ought to be protected from phase II enzymes, the hydroxyl groups. Through chemical derivatization (performed by the group of prof. Cristina Paradisi) the hydroxyl groups were reversibly protected with pro-moieties. The choice of linker group and of the pro-moiety is of fundamental importance to construct a useful prodrug. We intend prodrugs as therapeutic molecules designed for oral administration. This route of administration demands a suitable stability in gastric and intestinal environments, and a moderate instability in other physiological matrices (e.g. blood, tissues, extracellular fluids) so as to regenerate the active polyphenol once in the latter. During my PhD project we have optimized the two key components of the prodrug, the bond and the substituent group, working with Resveratrol, and we have then applied the results to Pterostilbene.
I started my project working on acetal derivatives of Resveratrol. We produced and tested a series of derivatives bearing short ethyleneglycol oligomers (OEG) linked to the phenolic oxygens via acetal/formal/ketal bonds. Through ex vivo and in vivo tests we have identified the acetal derivative Resv-O-CH(CH3)-OR, with R = tetrameric OEG, as the most promising prodrug of this series (chapter 1, “Acetal derivatives as prodrugs of resveratrol”).
Complete deprotection to give Resveratrol was however rather slow. We thus decided to test new derivatives based on a different bond system, and different substituent groups. Chapter 2, “New water-soluble carbamate ester derivatives of resveratrol”, presents the results obtained with Resveratrol derivatives bearing a PEG 350 or a sugar promoiety joined to the stilbenoid core through a N,N-di-substituted carbamate ester functionality. These molecules present the advantage of an increased water solubility, while maintaining to some degree the ability to permeate membranes. However, the high stability of these molecules was again problematic.
The stability vs. hydrolysis of the carbamate bond can be modulated varying the number and characteristics of the substituents on the Nitrogen atom; we tested therefore the N-mono-substitute carbamate group, which we expected to be more labile than its di-substitued analog. Chapters 3 and 4 (respectively “N-monosubstituted carbamate ester derivatives of resveratrol” and “Synthesis and evaluation of hydrophilic carbamate ester analogos of resveratrol”) present two series of derivatives of Resveratrol comprising amino acids, short ethyleneglycol oligomers (OEG) or sugar promoities linked to the scaffold via this group. The N-mono-substituted version of the carbamate bond shows high stability in acid, a suitable stability at near-neutral pH, and it undergoes hydrolysis with opportune kinetics in rat blood. The stability of these molecules depends in part on the substituent group on Nitrogen. However most of our derivatives hydrolyzed with a time course compatible with their use as prodrugs of Resveratrol (chapter 3).
Besides its rapid phase II metabolism, Resveratrol is also poorly soluble in water. Its administration is therefore usually as pills or with excipients. Water-soluble prodrugs would facilitate Resveratrol administration, especially if given chronically. In chapter 4 I present Resveratrol derivatives in which all three, two or one hydroxyl group(s) are incorporated into N-monosubstituted carbamate ester moieties; in these molecules the pro-moiety is a polyhydroxylated group (dihydroxypropyl or 6-deoxygalactose), and confers high water solubility. Galactosyl derivatives were substantially confined to the intestine, where they accumulated especially in the lower segments, undergoing the progressive loss of the protecting groups. Dihydroxypropyl derivatives instead were partly absorbed. Notably, the best results were achieved using mono-substituted derivatives.
I have then applied the knowledge and know-how gained working with Resveratrol to Pterostilbene, the 3,5-dimethylated analogue of Resveratrol. Since Pterostilbene is still poorly characterized from a pharmacological point of view we first of all performed a detailed analysis of the distribution of the molecule and its major metabolite in the organs of rat after its oral administration (chapter 5, “Pharmacokinetics and tissue distribution of pterostilbene in the rat”). The levels of Pterostilbene in the organs were much higher than those measured in blood. Nonetheless, its sulfate was the predominant specie in all tissues examined except the brain.
We tested a small library of pro-drugs of Pterostilbene bearing amino acids linked to the phenolic oxygen via the N-monosubstitute carbamate ester group. As expected, the rates of hydrolysis of these derivatives fell in a range suitable for their use as prodrugs. Absorption of Pterostilbene derivatives bearing apolar amino acids was greatly increased (chapter 6, “Boosting pterostilbene’s effects: a prodrug approach”). Apart from an intense and sustained absorption from the intestinal wall, a few precursors were notable for the levels of Pterostilbene they regenerated in blood. One of these compounds was selected as the most promising one and its distribution in rat organs was analyzed, following the same criteria adopted for Pterostilbene (described in chapter 5). The prodrug itself was the major specie measured in all organs examined, except the brain, while levels of the sulfate metabolite were decreased and those of regenerated Pterostilbene increased in most of the organs examined (in comparison with the administration of Pterostilbene itself). Prodrugs can thus be a useful tool to increase the bioavailability of some polyphenols.
In the second phase of my PhD project I conducted an investigation, still to be completed at this point, of the cellular processes set in motion by Pterostilbene and Resveratrol. For this purpose we adopted in vitro and in vivo approaches, presented here in two separate chapters, focused on the induction of autophagy and on the modulation of aged-impaired cognitive processes, respectively
Finally, during my doctoral training I have also been involved in other ongoing projects in my group. This involvement has led to my presence in the author list of three publications, which I include in this thesis as chapters 9, 10 and 11.

Abstract (italiano)

Questa tesi riguarda aspetti della farmacologia di due polifenoli: il Resveratrolo e lo Pterostilbene.
Queste molecole di origine vegetale sono oggetto di intensa ricerca alla luce dei loro effetti biologici e biomedici, d’interesse per varie e distinte patologie legate all’età, infiammazione, cancro, obesità, neurodegenerazione e diabete. Tuttavia i meccanismi alla base dell’attività del Resveratrolo ed in particolare dello Pterostilbene non sono completamente noti. Inoltre, la presenza di gruppi idrossilici liberi (caratteristica tipica dei polifenoli) rende queste molecole un buon substrato per gli enzimi del metabolismo di fase II, la cui attività ne limita fortemente la biodisponibilità e lo sfruttamento farmacologico.
Nel corso del mio dottorato mi sono occupato di entrambi questi temi. Descriverò prima il lavoro fatto per aumentare la biodisponibilità delle molecole precedentemente menzionate. In secondo luogo riassumerò le indagini sui meccanismi molecolari che sottendono l’attività dello Pterostilbene e del Resveratrolo.
La strategia adottata dal mio gruppo per aumentare la biodisponibilità di questi polifenoli, considerati alla stregua di farmaci, si basa sull’uso di pro-farmaci. I pro-farmaci sono essenzialmente versioni protette di una determinata molecola. Il Resveratrolo in particolare presenta tre siti principali che dovrebbero essere protetti dagli enzimi del metabolismo di fase II, i gruppo idrossilici. Attraverso un processo di derivatizzazione chimica (svolto dal gruppo della prof.ssa Cristina Paradisi) i gruppi idrossilici sono stati protetti con dei gruppi sostituenti. La scelta della funzionalità chimica e dei sostituenti usati per la protezione è fondamentale per ottenere un pro-farmaco utile. Noi intendiamo i pro-farmaci come molecole terapeutiche adatte per la somministrazione orale. Questa via di somministrazione presume un’elevata stabilità negli ambienti gastrici ed intestinali, seguita da una moderata instabilità in altri ambiti fisiologici (sangue, tessuti, fluidi extracellulari) così da rigenerare il polifenolo naturale, attivo. Durante il mio progetto di dottorato abbiamo ottimizzato questi componenti dei pro-farmaci, il legame ed il gruppo sostituente, lavorando con il Resveratrolo, e poi abbiamo applicato i risultati ottenuti allo Pterostilbene.
Ho iniziato lavorando su derivati acetalici del Resveratrolo. Abbiamo prodotto e testato una serie di composti “decorati” con brevi oligomeri di glicole etilenico legati agli ossigeni fenolici con dei legami di tipo acetalico. Tramite esperimenti ex vivo ed in vivo abbiamo identificato la molecola con quattro unità di glicole etilenico ed il legame acetale propriamente detto (Resv-O-CH(CH3)-OR) come pro-farmaco più promettente di questa serie di composti (capitolo 1: “Acetal derivatives as prodrugs of resveratrol”).
La deprotezione completa per rigenerare Resveratrolo è risultata tuttavia piuttosto lenta. Abbiamo quindi deciso di testare nuovi derivati aventi un diverso legame chimico e diversi gruppi sostituenti. Il capitolo 2, “New water-soluble carbamate ester derivatives of resveratrol”, presenta i risultati ottenuti con derivati del Resveratrolo recanti PEG 350 o sostituenti di tipo zuccherino incorporati come carbammato N,N-di-sostituito. Queste molecole presentano il vantaggio di essere più idrosolubili, mantenendo al contempo la stessa capacità di permeazione delle membrane cellulari. Tuttavia, l’elevata stabilità di questi composti è risultata ancora problematica.
La stabilità del legame carbammico può essere modulata variando il numero e caratteristiche dei sostituenti sull’atomo di azoto; abbiamo quindi testato il legame estere carbammato N-mono-sostituito, che ci attendevamo fosse più labile rispetto al suo equivalente di-sostituito. I capitoli 3 e 4 (rispettivamente “N-monosubstituted carbamate ester derivatives of resveratrol” and “Synthesis and evaluation of hydrophilic carbamate ester analogos of resveratrol”) presentano due serie di derivati del Resveratrolo contenenti aminoacidi, brevi oligomeri di glicole etilenico o sostituenti zuccherini collegati allo “scaffold” stilbenico con questo gruppo. La versione N-mono-sostituita del legame estere carbammato presenta un’elevata stabilità in ambiente acido, una buona stabilità a pH neutro e viene idrolizzata con un’opportuna cinetica in sangue di ratto. La stabilità di questi composti dipende in parte dal gruppo sostituente legato all’azoto. Tuttavia la maggior parte di essi ha dimostrato una reattività idonea all’uso come pro-farmaci del Resveratrolo (capitolo 3).
Oltre a subire un rapido metabolismo di fase II, il Resveratrolo è anche poco solubile in acqua. La sua somministrazione è limitata a pillole o all’uso di eccipienti. Derivati del Resveratrolo solubili in acqua potrebbero quindi facilitarne la somministrazione, specialmente se cronica. Nel capitolo 4 presento derivati del Resveratrolo tri- di- e mono-derivatizzati come esteri carbammici N-monosostituiti; in queste molecole il gruppo sostituente è di tipo poliidrossilico (diidrossipropile o 6-deossigalattosio), e conferisce un’elevata solubilità in acqua. I derivati con il galattosio sono sostanzialmente confinati nell’intestino, dove si accumulano in particolare nei tratti finali, subendovi la progressiva perdita dei gruppi protettori. I derivati con il diidrossipropile vengono invece assorbiti dall’intestino. In particolare, i risultati migliori sono stati ottenuti somministrando i derivati mono-sostituiti.
Ho quindi applicato le conoscenze acquisite lavorando con il Resveratrolo allo Pterostilbene, l’analogo 3,5-dimetilato del Resveratrolo. Poiché lo Pterostilbene è ancora poco caratterizzato abbiamo innanzitutto eseguito una dettagliata analisi sulla distribuzione della molecola negli organi dopo la sua somministrazione orale (capitolo 5, “Pharmacokinetics and tissue distribution of pterostilbene in the rat”). I livelli di Pterostilbene negli organi sono risultati molto elevati in paragone a quelli misurati nel sangue. Tuttavia, eccetto che nel cervello, il suo metabolita solfato è risultato la specie più abbondante nei tessuti esaminati. Abbiamo quindi testato una piccola libreria di pro-farmaci dello Pterostilbene basati sul legame carbammico N-monosostituito e amminoacidi naturali. Come ci attendavamo, la stabilità di questi derivati è compresa in un intervallo utile per l’uso come pro-farmaci. L’assorbimento dei derivati recanti amminoacidi apolari è fortemente incrementato (capitolo 6, “Boosting pterostilbene’s effects: a prodrug approach”). Oltre ad un intenso e sostenuto assorbimento intestinale, alcuni precursori si sono distinti per i livelli di Pterostilbene rigenerati nel sangue. Uno di questi composti è stato selezionato come più promettente e la sua distribuzione negli organi dopo somministrazione orale è stata mappata seguendo gli stessi criteri adottati per lo Pterostilbene (descritti nel capitolo 5). Il derivato stesso è stato la specie più abbondante misurata negli organi esaminati, eccetto che nel cervello, mentre i livelli del metabolita solfato erano diminuiti e quelli dello Pterostilbene aumentati nella maggior parte degli organi esaminati. I pro-farmaci possono quindi essere utili strumenti per aumentare la biodisponibilità di alcuni polifenoli.
Nella seconda parte del mio dottorato ho condotto indagini, ancora in corso, su aspetti dei meccanismi cellulari con cui agiscono Resveratrolo e Pterostilbene. A tal scopo abbiamo adottato un duplice approccio, sia in vitro che in vivo, presentati in questa sede in due diversi capitoli, focalizzati in particolare sull’induzione di autofagia e sulla modulazione dei processi cognitivi deteriorati dall’età, rispettivamente.
Infine, nel corso del mio dottorato sono stato coinvolto in altri progetti in corso nel gruppo. Questa partecipazione ha fatto sì che io fossi incluso fra gli autori di tre pubblicazioni, che includo in questa tesi come capitoli 9, 10 ed 11.

Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Zoratti, Mario
Dottorato (corsi e scuole):Ciclo 27 > scuole 27 > BIOSCIENZE E BIOTECNOLOGIE > BIOLOGIA CELLULARE
Data di deposito della tesi:27 Gennaio 2015
Anno di Pubblicazione:27 Gennaio 2015
Parole chiave (italiano / inglese):Resveratrol, Pterostilbene, pharmacokinetics, prodrugs, autophagy, cognitive aging
Settori scientifico-disciplinari MIUR:Area 05 - Scienze biologiche > BIO/10 Biochimica
Area 05 - Scienze biologiche > BIO/15 Biologia farmaceutica
Struttura di riferimento:Centri > Centro Interdipartimentale di servizi A. Vallisneri
Dipartimenti > Dipartimento di Scienze Biomediche
Codice ID:7610
Depositato il:12 Nov 2015 12:29
Simple Metadata
Full Metadata
EndNote Format


I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

References: Cerca con Google

1. Quideau, S.; Deffieux, D.; Douat-Casassus, C.; Pouysegu, L. Plant polyphenols: chemical properties, biological activities, and synthesis. Angewandte Chemie (International ed. in English) 2011, 50, (3), 586-621. Cerca con Google

2. Thaler, J.; Fidantsef, A.; Duffey, S.; Bostock, R. Trade-Offs in Plant Defense Against Pathogens and Herbivores: A Field Demonstration of Chemical Elicitors of Induced Resistance. J Chem Ecol 1999, 25, (7), 1597-1609. Cerca con Google

3. Pandey, K. B.; Rizvi, S. I. Plant polyphenols as dietary antioxidants in human health and disease. Oxidative medicine and cellular longevity 2009, 2, (5), 270-8. Cerca con Google

4. Frohnmeyer, H.; Staiger, D. Ultraviolet-B radiation-mediated responses in plants. Balancing damage and protection. Plant physiology 2003, 133, (4), 1420-8. Cerca con Google

5. Ke, D.; Saltveit, M. E. Plant hormone interaction and phenolic metabolism in the regulation of russet spotting in iceberg lettuce. Plant physiology 1988, 88, (4), 1136-40. Cerca con Google

6. Manach, C.; Mazur, A.; Scalbert, A. Polyphenols and prevention of cardiovascular diseases. Current opinion in lipidology 2005, 16, (1), 77-84. Cerca con Google

7. Scalbert, A.; Johnson, I. T.; Saltmarsh, M. Polyphenols: antioxidants and beyond. The American journal of clinical nutrition 2005, 81, (1 Suppl), 215s-217s. Cerca con Google

8. Siriwardhana, N.; Kalupahana, N. S.; Cekanova, M.; LeMieux, M.; Greer, B.; Moustaid-Moussa, N. Modulation of adipose tissue inflammation by bioactive food compounds. The Journal of nutritional biochemistry 2013, 24, (4), 613-23. Cerca con Google

9. Li, A. N.; Li, S.; Zhang, Y. J.; Xu, X. R.; Chen, Y. M.; Li, H. B. Resources and biological activities of natural polyphenols. Nutrients 2014, 6, (12), 6020-47. Cerca con Google

10. Malavolta, M.; Costarelli, L.; Giacconi, R.; Piacenza, F.; Basso, A.; Pierpaoli, E.; Marchegiani, F.; Cardelli, M.; Provinciali, M.; Mocchegiani, E. Modulators of cellular senescence: mechanisms, promises, and challenges from in vitro studies with dietary bioactive compounds. Nutrition research (New York, N.Y.) 2014, 34, (12), 1017-1035. Cerca con Google

11. Barrajon-Catalan, E.; Herranz-Lopez, M.; Joven, J.; Segura-Carretero, A.; Alonso-Villaverde, C.; Menendez, J. A.; Micol, V. Molecular promiscuity of plant polyphenols in the management of age-related diseases: far beyond their antioxidant properties. Advances in experimental medicine and biology 2014, 824, 141-59. Cerca con Google

12. Wang, S.; Moustaid-Moussa, N.; Chen, L.; Mo, H.; Shastri, A.; Su, R.; Bapat, P.; Kwun, I.; Shen, C. L. Novel insights of dietary polyphenols and obesity. The Journal of nutritional biochemistry 2014, 25, (1), 1-18. Cerca con Google

13. Chu, A. J. Antagonism by bioactive polyphenols against inflammation: a systematic view. Inflammation & allergy drug targets 2014, 13, (1), 34-64. Cerca con Google

14. Constant, J. Alcohol, ischemic heart disease, and the French paradox. Coronary artery disease 1997, 8, (10), 645-9. Cerca con Google

15. Kopp, P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? European journal of endocrinology / European Federation of Endocrine Societies 1998, 138, (6), 619-20. Cerca con Google

16. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nature reviews. Drug discovery 2006, 5, (6), 493-506. Cerca con Google

17. Harikumar, K. B.; Aggarwal, B. B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell cycle (Georgetown, Tex.) 2008, 7, (8), 1020-35. Cerca con Google

18. Pervaiz, S.; Holme, A. L. Resveratrol: its biologic targets and functional activity. Antioxidants & redox signaling 2009, 11, (11), 2851-97. Cerca con Google

19. Shakibaei, M.; Harikumar, K. B.; Aggarwal, B. B. Resveratrol addiction: to die or not to die. Molecular nutrition & food research 2009, 53, (1), 115-28. Cerca con Google

20. Widlund, A. L.; Baur, J. A.; Vang, O. mTOR: more targets of resveratrol? Expert reviews in molecular medicine 2013, 15, e10. Cerca con Google

21. Temraz, S.; Mukherji, D.; Shamseddine, A. Potential targets for colorectal cancer prevention. International journal of molecular sciences 2013, 14, (9), 17279-303. Cerca con Google

22. Bastianetto, S.; Menard, C.; Quirion, R. Neuroprotective action of resveratrol. Biochimica et biophysica acta 2014. Cerca con Google

23. Ma, T.; Tan, M.; Yu, J.; Tan, L. Resveratrol as a Therapeutic Agent for Alzheimer's Disease. BioMed research international 2014, 2014, 350516. Cerca con Google

24. Aguirre, L.; Fernandez-Quintela, A.; Arias, N.; Portillo, M. P. Resveratrol: anti-obesity mechanisms of action. Molecules (Basel, Switzerland) 2014, 19, (11), 18632-55. Cerca con Google

25. Paul, S.; Rimando, A. M.; Lee, H. J.; Ji, Y.; Reddy, B. S.; Suh, N. Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer prevention research (Philadelphia, Pa.) 2009, 2, (7), 650-7. Cerca con Google

26. Paul, S.; DeCastro, A. J.; Lee, H. J.; Smolarek, A. K.; So, J. Y.; Simi, B.; Wang, C. X.; Zhou, R.; Rimando, A. M.; Suh, N. Dietary intake of pterostilbene, a constituent of blueberries, inhibits the beta-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis 2010, 31, (7), 1272-8. Cerca con Google

27. Nutakul, W.; Sobers, H. S.; Qiu, P.; Dong, P.; Decker, E. A.; McClements, D. J.; Xiao, H. Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: a side-by-side comparison. Journal of agricultural and food chemistry 2011, 59, (20), 10964-70. Cerca con Google

28. McCormack, D.; McFadden, D. Pterostilbene and cancer: current review. The Journal of surgical research 2012, 173, (2), e53-61. Cerca con Google

29. McCormack, D.; McFadden, D. A review of pterostilbene antioxidant activity and disease modification. Oxidative medicine and cellular longevity 2013, 2013, 575482. Cerca con Google

30. Chang, J.; Rimando, A.; Pallas, M.; Camins, A.; Porquet, D.; Reeves, J.; Shukitt-Hale, B.; Smith, M. A.; Joseph, J. A.; Casadesus, G. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiology of aging 2012, 33, (9), 2062-71. Cerca con Google

31. Estrela, J. M.; Ortega, A.; Mena, S.; Rodriguez, M. L.; Asensi, M. Pterostilbene: Biomedical applications. Critical reviews in clinical laboratory sciences 2013, 50, (3), 65-78. Cerca con Google

32. Yeo, S. C.; Ho, P. C.; Lin, H. S. Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Molecular nutrition & food research 2013, 57, (6), 1015-25. Cerca con Google

33. Rahman, I.; Biswas, S. K.; Kirkham, P. A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochemical pharmacology 2006, 72, (11), 1439-52. Cerca con Google

34. De Marchi, U.; Biasutto, L.; Garbisa, S.; Toninello, A.; Zoratti, M. Quercetin can act either as an inhibitor or an inducer of the mitochondrial permeability transition pore: A demonstration of the ambivalent redox character of polyphenols. Biochimica et biophysica acta 2009, 1787, (12), 1425-32. Cerca con Google

35. Cao, G.; Sofic, E.; Prior, R. L. Antioxidant and prooxidant behavior of flavonoids: structure-activity relationships. Free radical biology & medicine 1997, 22, (5), 749-60. Cerca con Google

36. Kagan, V. E.; Tyurina, Y. Y. Recycling and redox cycling of phenolic antioxidants. Annals of the New York Academy of Sciences 1998, 854, 425-34. Cerca con Google

37. Galati, G.; Chan, T.; Wu, B.; O'Brien, P. J. Glutathione-dependent generation of reactive oxygen species by the peroxidase-catalyzed redox cycling of flavonoids. Chemical research in toxicology 1999, 12, (6), 521-5. Cerca con Google

38. Kessler, M.; Ubeaud, G.; Jung, L. Anti- and pro-oxidant activity of rutin and quercetin derivatives. The Journal of pharmacy and pharmacology 2003, 55, (1), 131-42. Cerca con Google

39. Kanadzu, M.; Lu, Y.; Morimoto, K. Dual function of (--)-epigallocatechin gallate (EGCG) in healthy human lymphocytes. Cancer letters 2006, 241, (2), 250-5. Cerca con Google

40. Bellion, P.; Olk, M.; Will, F.; Dietrich, H.; Baum, M.; Eisenbrand, G.; Janzowski, C. Formation of hydrogen peroxide in cell culture media by apple polyphenols and its effect on antioxidant biomarkers in the colon cell line HT-29. Molecular nutrition & food research 2009, 53, (10), 1226-36. Cerca con Google

41. Long, L. H.; Hoi, A.; Halliwell, B. Instability of, and generation of hydrogen peroxide by, phenolic compounds in cell culture media. Archives of biochemistry and biophysics 2010, 501, (1), 162-9. Cerca con Google

42. Halliwell, B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? Archives of biochemistry and biophysics 2008, 476, (2), 107-12. Cerca con Google

43. Halliwell, B. Cell culture, oxidative stress, and antioxidants: avoiding pitfalls. Biomedical journal 2014, 37, (3), 99-105. Cerca con Google

44. Murphy, M. P. How mitochondria produce reactive oxygen species. The Biochemical journal 2009, 417, (1), 1-13. Cerca con Google

45. Lambert, A. J.; Brand, M. D. Reactive oxygen species production by mitochondria. Methods in molecular biology (Clifton, N.J.) 2009, 554, 165-81. Cerca con Google

46. Brand, M. D. The sites and topology of mitochondrial superoxide production. Experimental gerontology 2010, 45, (7-8), 466-72. Cerca con Google

47. Biasutto, L.; Szabo, I.; Zoratti, M. Mitochondrial effects of plant-made compounds. Antioxidants & redox signaling 2011, 15, (12), 3039-59. Cerca con Google

48. Sena, L. A.; Chandel, N. S. Physiological roles of mitochondrial reactive oxygen species. Molecular cell 2012, 48, (2), 158-67. Cerca con Google

49. Calabrese, E. J.; Mattson, M. P.; Calabrese, V. Resveratrol commonly displays hormesis: occurrence and biomedical significance. Human & experimental toxicology 2010, 29, (12), 980-1015. Cerca con Google

50. Calabrese, E. J. Hormesis is central to toxicology, pharmacology and risk assessment. Human & experimental toxicology 2010, 29, (4), 249-61. Cerca con Google

51. Ristow, M.; Zarse, K. How increased oxidative stress promotes longevity and metabolic health: The concept of mitochondrial hormesis (mitohormesis). Experimental gerontology 2010, 45, (6), 410-8. Cerca con Google

52. Borriello, A.; Bencivenga, D.; Caldarelli, I.; Tramontano, A.; Borgia, A.; Pirozzi, A. V.; Oliva, A.; Della Ragione, F. Resveratrol and cancer treatment: is hormesis a yet unsolved matter? Current pharmaceutical design 2013, 19, (30), 5384-93. Cerca con Google

53. Murakami, A. Dose-dependent functionality and toxicity of green tea polyphenols in experimental rodents. Archives of biochemistry and biophysics 2014, 557, 3-10. Cerca con Google

54. Yun, J.; Finkel, T. Mitohormesis. Cell metabolism 2014, 19, (5), 757-66. Cerca con Google

55. Ristow, M. Unraveling the truth about antioxidants: mitohormesis explains ROS-induced health benefits. Nature medicine 2014, 20, (7), 709-11. Cerca con Google

56. Blagosklonny, M. V. Hormesis does not make sense except in the light of TOR-driven aging. Aging 2011, 3, (11), 1051-62. Cerca con Google

57. Li, C.; Xu, X.; Tao, Z.; Wang, X. J.; Pan, Y. Resveratrol dimers, nutritional components in grape wine, are selective ROS scavengers and weak Nrf2 activators. Food chemistry 2015, 173, 218-23. Cerca con Google

58. Soeur, J.; Eilstein, J.; Lereaux, G.; Jones, C.; Marrot, L. Skin resistance to oxidative stress induced by resveratrol: From Nrf2 activation to GSH biosynthesis. Free radical biology & medicine 2015, 78, 213-23. Cerca con Google

59. Xia, N.; Forstermann, U.; Li, H. Resveratrol and endothelial nitric oxide. Molecules (Basel, Switzerland) 2014, 19, (10), 16102-21. Cerca con Google

60. Singh, B.; Shoulson, R.; Chatterjee, A.; Ronghe, A.; Bhat, N. K.; Dim, D. C.; Bhat, H. K. Resveratrol inhibits estrogen-induced breast carcinogenesis through induction of NRF2-mediated protective pathways. Carcinogenesis 2014, 35, (8), 1872-80. Cerca con Google

61. Simao, F.; Matte, A.; Pagnussat, A. S.; Netto, C. A.; Salbego, C. G. Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3beta and CREB through PI3-K/Akt pathways. The European journal of neuroscience 2012, 36, (7), 2899-905. Cerca con Google

62. Liao, Z.; Liu, D.; Tang, L.; Yin, D.; Yin, S.; Lai, S.; Yao, J.; He, M. Long-term oral resveratrol intake provides nutritional preconditioning against myocardial ischemia/reperfusion injury: involvement of VDAC1 down-regulation. Molecular nutrition & food research 2014. Cerca con Google

63. Lu, Z.; Zhang, Y.; Liu, H.; Yuan, J.; Zheng, Z.; Zou, G. Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. Journal of fluorescence 2007, 17, (5), 580-7. Cerca con Google

64. CN, N. s.-K.; St-Louis, C.; Beauregard, M.; Subirade, M.; Carpentier, R.; Hotchandani, S.; Tajmir-Riahi, H. A. Resveratrol binding to human serum albumin. Journal of biomolecular structure & dynamics 2006, 24, (3), 277-83. Cerca con Google

65. Bourassa, P.; Kanakis, C. D.; Tarantilis, P.; Pollissiou, M. G.; Tajmir-Riahi, H. A. Resveratrol, genistein, and curcumin bind bovine serum albumin. The journal of physical chemistry. B 2010, 114, (9), 3348-54. Cerca con Google

66. Latruffe, N.; Menzel, M.; Delmas, D.; Buchet, R.; Lancon, A. Compared binding properties between resveratrol and other polyphenols to plasmatic albumin: consequences for the health protecting effect of dietary plant microcomponents. Molecules (Basel, Switzerland) 2014, 19, (11), 17066-77. Cerca con Google

67. Bourassa, P.; Bariyanga, J.; Tajmir-Riahi, H. A. Binding sites of resveratrol, genistein, and curcumin with milk alpha- and beta-caseins. The journal of physical chemistry. B 2013, 117, (5), 1287-95. Cerca con Google

68. Liang, L.; Tajmir-Riahi, H. A.; Subirade, M. Interaction of beta-lactoglobulin with resveratrol and its biological implications. Biomacromolecules 2008, 9, (1), 50-6. Cerca con Google

69. Kanakis, C. D.; Tarantilis, P. A.; Polissiou, M. G.; Tajmir-Riahi, H. A. Probing the binding sites of resveratrol, genistein, and curcumin with milk beta-lactoglobulin. Journal of biomolecular structure & dynamics 2013, 31, (12), 1455-66. Cerca con Google

70. Hsieh, T. C.; Wang, Z.; Deng, H.; Wu, J. M. Identification of glutathione sulfotransferase-pi (GSTP1) as a new resveratrol targeting protein (RTP) and studies of resveratrol-responsive protein changes by resveratrol affinity chromatography. Anticancer research 2008, 28, (1a), 29-36. Cerca con Google

71. Gledhill, J. R.; Montgomery, M. G.; Leslie, A. G.; Walker, J. E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proceedings of the National Academy of Sciences of the United States of America 2007, 104, (34), 13632-7. Cerca con Google

72. Slater, S. J.; Seiz, J. L.; Cook, A. C.; Stagliano, B. A.; Buzas, C. J. Inhibition of protein kinase C by resveratrol. Biochimica et biophysica acta 2003, 1637, (1), 59-69. Cerca con Google

73. Lin, H. Y.; Lansing, L.; Merillon, J. M.; Davis, F. B.; Tang, H. Y.; Shih, A.; Vitrac, X.; Krisa, S.; Keating, T.; Cao, H. J.; Bergh, J.; Quackenbush, S.; Davis, P. J. Integrin alphaVbeta3 contains a receptor site for resveratrol. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2006, 20, (10), 1742-4. Cerca con Google

74. Wang, Z.; Hsieh, T. C.; Zhang, Z.; Ma, Y.; Wu, J. M. Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochemical and biophysical research communications 2004, 323, (3), 743-9. Cerca con Google

75. Kutil, Z.; Temml, V.; Maghradze, D.; Pribylova, M.; Dvorakova, M.; Schuster, D.; Vanek, T.; Landa, P. Impact of wines and wine constituents on cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase catalytic activity. Mediators of inflammation 2014, 2014, 178931. Cerca con Google

76. Park, S. J.; Ahmad, F.; Philp, A.; Baar, K.; Williams, T.; Luo, H.; Ke, H.; Rehmann, H.; Taussig, R.; Brown, A. L.; Kim, M. K.; Beaven, M. A.; Burgin, A. B.; Manganiello, V.; Chung, J. H. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012, 148, (3), 421-33. Cerca con Google

77. Zhao, P.; Chen, S. K.; Cai, Y. H.; Lu, X.; Li, Z.; Cheng, Y. K.; Zhang, C.; Hu, X.; He, X.; Luo, H. B. The molecular basis for the inhibition of phosphodiesterase-4D by three natural resveratrol analogs. Isolation, molecular docking, molecular dynamics simulations, binding free energy, and bioassay. Biochimica et biophysica acta 2013, 1834, (10), 2089-96. Cerca con Google

78. Calleri, E.; Pochetti, G.; Dossou, K. S.; Laghezza, A.; Montanari, R.; Capelli, D.; Prada, E.; Loiodice, F.; Massolini, G.; Bernier, M.; Moaddel, R. Resveratrol and its metabolites bind to PPARs. Chembiochem : a European journal of chemical biology 2014, 15, (8), 1154-60. Cerca con Google

79. Han, Y. S.; Bastianetto, S.; Dumont, Y.; Quirion, R. Specific plasma membrane binding sites for polyphenols, including resveratrol, in the rat brain. The Journal of pharmacology and experimental therapeutics 2006, 318, (1), 238-45. Cerca con Google

80. Bastianetto, S.; Dumont, Y.; Han, Y.; Quirion, R. Comparative neuroprotective properties of stilbene and catechin analogs: action via a plasma membrane receptor site? CNS neuroscience & therapeutics 2009, 15, (1), 76-83. Cerca con Google

81. Bastianetto, S.; Dumont, Y.; Duranton, A.; Vercauteren, F.; Breton, L.; Quirion, R. Protective action of resveratrol in human skin: possible involvement of specific receptor binding sites. PloS one 2010, 5, (9), e12935. Cerca con Google

82. Tachibana, H.; Koga, K.; Fujimura, Y.; Yamada, K. A receptor for green tea polyphenol EGCG. Nature structural & molecular biology 2004, 11, (4), 380-1. Cerca con Google

83. Umeda, D.; Yano, S.; Yamada, K.; Tachibana, H. Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. The Journal of biological chemistry 2008, 283, (6), 3050-8. Cerca con Google

84. Fujimura, Y.; Sumida, M.; Sugihara, K.; Tsukamoto, S.; Yamada, K.; Tachibana, H. Green tea polyphenol EGCG sensing motif on the 67-kDa laminin receptor. PloS one 2012, 7, (5), e37942. Cerca con Google

85. Tsukamoto, S.; Hirotsu, K.; Kumazoe, M.; Goto, Y.; Sugihara, K.; Suda, T.; Tsurudome, Y.; Suzuki, T.; Yamashita, S.; Kim, Y.; Huang, Y.; Yamada, K.; Tachibana, H. Green tea polyphenol EGCG induces lipid-raft clustering and apoptotic cell death by activating protein kinase Cdelta and acid sphingomyelinase through a 67 kDa laminin receptor in multiple myeloma cells. The Biochemical journal 2012, 443, (2), 525-34. Cerca con Google

86. Kumazoe, M.; Sugihara, K.; Tsukamoto, S.; Huang, Y.; Tsurudome, Y.; Suzuki, T.; Suemasu, Y.; Ueda, N.; Yamashita, S.; Kim, Y.; Yamada, K.; Tachibana, H. 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis. The Journal of clinical investigation 2013, 123, (2), 787-99. Cerca con Google

87. Menard, C.; Bastianetto, S.; Quirion, R. Neuroprotective effects of resveratrol and epigallocatechin gallate polyphenols are mediated by the activation of protein kinase C gamma. Frontiers in cellular neuroscience 2013, 7, 281. Cerca con Google

88. Patel, R.; Apostolatos, A.; Carter, G.; Ajmo, J.; Gali, M.; Cooper, D. R.; You, M.; Bisht, K. S.; Patel, N. A. Protein kinase C delta (PKCdelta) splice variants modulate apoptosis pathway in 3T3L1 cells during adipogenesis: identification of PKCdeltaII inhibitor. The Journal of biological chemistry 2013, 288, (37), 26834-46. Cerca con Google

89. Kundu, J. K.; Shin, Y. K.; Kim, S. H.; Surh, Y. J. Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 2006, 27, (7), 1465-74. Cerca con Google

90. Jo, J. Y.; Gonzalez de Mejia, E.; Lila, M. A. Catalytic inhibition of human DNA topoisomerase II by interactions of grape cell culture polyphenols. Journal of agricultural and food chemistry 2006, 54, (6), 2083-7. Cerca con Google

91. Dhar, S.; Kumar, A.; Li, K.; Tzivion, G.; Levenson, A. S. Resveratrol regulates PTEN/Akt pathway through inhibition of MTA1/HDAC unit of the NuRD complex in prostate cancer. Biochimica et biophysica acta 2015, 1853, (2), 265-75. Cerca con Google

92. Um, J. H.; Park, S. J.; Kang, H.; Yang, S.; Foretz, M.; McBurney, M. W.; Kim, M. K.; Viollet, B.; Chung, J. H. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59, (3), 554-63. Cerca con Google

93. Canto, C.; Jiang, L. Q.; Deshmukh, A. S.; Mataki, C.; Coste, A.; Lagouge, M.; Zierath, J. R.; Auwerx, J. Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell metabolism 2010, 11, (3), 213-9. Cerca con Google

94. Canto, C.; Gerhart-Hines, Z.; Feige, J. N.; Lagouge, M.; Noriega, L.; Milne, J. C.; Elliott, P. J.; Puigserver, P.; Auwerx, J. AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 2009, 458, (7241), 1056-60. Cerca con Google

95. Pacholec, M.; Bleasdale, J. E.; Chrunyk, B.; Cunningham, D.; Flynn, D.; Garofalo, R. S.; Griffith, D.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. The Journal of biological chemistry 2010, 285, (11), 8340-51. Cerca con Google

96. Lakshminarasimhan, M.; Rauh, D.; Schutkowski, M.; Steegborn, C. Sirt1 activation by resveratrol is substrate sequence-selective. Aging 2013, 5, (3), 151-4. Cerca con Google

97. Lakshminarasimhan, M.; Curth, U.; Moniot, S.; Mosalaganti, S.; Raunser, S.; Steegborn, C. Molecular architecture of the human protein deacetylase Sirt1 and its regulation by AROS and resveratrol. Bioscience reports 2013, 33, (3). Cerca con Google

98. Gertz, M.; Nguyen, G. T.; Fischer, F.; Suenkel, B.; Schlicker, C.; Franzel, B.; Tomaschewski, J.; Aladini, F.; Becker, C.; Wolters, D.; Steegborn, C. A molecular mechanism for direct sirtuin activation by resveratrol. PloS one 2012, 7, (11), e49761. Cerca con Google

99. Nguyen, G. T.; Gertz, M.; Steegborn, C. Crystal structures of Sirt3 complexes with 4'-bromo-resveratrol reveal binding sites and inhibition mechanism. Chemistry & biology 2013, 20, (11), 1375-85. Cerca con Google

100. Parihar, P.; Solanki, I.; Mansuri, M. L.; Parihar, M. S. Mitochondrial sirtuins: Emerging roles in metabolic regulations, energy homeostasis and diseases. Experimental gerontology 2015, 61c, 130-141. Cerca con Google

101. Kiran, S.; Anwar, T.; Kiran, M.; Ramakrishna, G. Sirtuin 7 in cell proliferation, stress and disease: Rise of the Seventh Sirtuin! Cellular signalling 2014. Cerca con Google

102. Zhu, Y.; Yan, Y.; Principe, D. R.; Zou, X.; Vassilopoulos, A.; Gius, D. SIRT3 and SIRT4 are mitochondrial tumor suppressor proteins that connect mitochondrial metabolism and carcinogenesis. Cancer & metabolism 2014, 2, 15. Cerca con Google

103. Masri, S.; Sassone-Corsi, P. Sirtuins and the circadian clock: bridging chromatin and metabolism. Science signaling 2014, 7, (342), re6. Cerca con Google

104. Choudhary, C.; Weinert, B. T.; Nishida, Y.; Verdin, E.; Mann, M. The growing landscape of lysine acetylation links metabolism and cell signalling. Nature reviews. Molecular cell biology 2014, 15, (8), 536-50. Cerca con Google

105. Russo, M. A.; Sansone, L.; Polletta, L.; Runci, A.; Rashid, M. M.; De Santis, E.; Vernucci, E.; Carnevale, I.; Tafani, M. Sirtuins and resveratrol-derived compounds: a model for understanding the beneficial effects of the Mediterranean diet. Endocrine, metabolic & immune disorders drug targets 2014, 14, (4), 300-8. Cerca con Google

106. Pirola, L.; Frojdo, S. Resveratrol: one molecule, many targets. IUBMB life 2008, 60, (5), 323-32. Cerca con Google

107. Zimmermann, G. R.; Lehar, J.; Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug discovery today 2007, 12, (1-2), 34-42. Cerca con Google

108. Wagner, H. Synergy research: approaching a new generation of phytopharmaceuticals. Fitoterapia 2011, 82, (1), 34-7. Cerca con Google

109. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Current drug targets 2011, 12, (1), 122-32. Cerca con Google

110. Rather, M. A.; Bhat, B. A.; Qurishi, M. A. Multicomponent phytotherapeutic approach gaining momentum: Is the "one drug to fit all" model breaking down? Phytomedicine : international journal of phytotherapy and phytopharmacology 2013, 21, (1), 1-14. Cerca con Google

111. Yang, Y.; Zhang, Z.; Li, S.; Ye, X.; Li, X.; He, K. Synergy effects of herb extracts: pharmacokinetics and pharmacodynamic basis. Fitoterapia 2014, 92, 133-47. Cerca con Google

112. Smoliga, J. M.; Baur, J. A.; Hausenblas, H. A. Resveratrol and health--a comprehensive review of human clinical trials. Molecular nutrition & food research 2011, 55, (8), 1129-41. Cerca con Google

113. Patel, K. R.; Scott, E.; Brown, V. A.; Gescher, A. J.; Steward, W. P.; Brown, K. Clinical trials of resveratrol. Annals of the New York Academy of Sciences 2011, 1215, 161-9. Cerca con Google

114. Tome-Carneiro, J.; Larrosa, M.; Gonzalez-Sarrias, A.; Tomas-Barberan, F. A.; Garcia-Conesa, M. T.; Espin, J. C. Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Current pharmaceutical design 2013, 19, (34), 6064-93. Cerca con Google

115. Subramanian, L.; Youssef, S.; Bhattacharya, S.; Kenealey, J.; Polans, A. S.; van Ginkel, P. R. Resveratrol: challenges in translation to the clinic--a critical discussion. Clinical cancer research : an official journal of the American Association for Cancer Research 2010, 16, (24), 5942-8. Cerca con Google

116. Planas, J. M.; Alfaras, I.; Colom, H.; Juan, M. E. The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters. Archives of biochemistry and biophysics 2012, 527, (2), 67-73. Cerca con Google

117. Neves, A. R.; Lucio, M.; Lima, J. L.; Reis, S. Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions. Current medicinal chemistry 2012, 19, (11), 1663-81. Cerca con Google

118. Walle, T. Bioavailability of resveratrol. Annals of the New York Academy of Sciences 2011, 1215, 9-15. Cerca con Google

119. Cottart, C. H.; Nivet-Antoine, V.; Laguillier-Morizot, C.; Beaudeux, J. L. Resveratrol bioavailability and toxicity in humans. Molecular nutrition & food research 2010, 54, (1), 7-16. Cerca con Google

120. Wenzel, E.; Somoza, V. Metabolism and bioavailability of trans-resveratrol. Molecular nutrition & food research 2005, 49, (5), 472-81. Cerca con Google

121. Azzolini, M.; La Spina, M.; Mattarei, A.; Paradisi, C.; Zoratti, M.; Biasutto, L. Pharmacokinetics and tissue distribution of pterostilbene in the rat. Molecular nutrition & food research 2014, 58, (11), 2122-32. Cerca con Google

122. Aires, V.; Limagne, E.; Cotte, A. K.; Latruffe, N.; Ghiringhelli, F.; Delmas, D. Resveratrol metabolites inhibit human metastatic colon cancer cells progression and synergize with chemotherapeutic drugs to induce cell death. Molecular nutrition & food research 2013, 57, (7), 1170-81. Cerca con Google

123. Derlindati, E.; Dall'Asta, M.; Ardigo, D.; Brighenti, F.; Zavaroni, I.; Crozier, A.; Del Rio, D. Quercetin-3-O-glucuronide affects the gene expression profile of M1 and M2a human macrophages exhibiting anti-inflammatory effects. Food & function 2012, 3, (11), 1144-52. Cerca con Google

124. Ruotolo, R.; Calani, L.; Fietta, E.; Brighenti, F.; Crozier, A.; Meda, C.; Maggi, A.; Ottonello, S.; Del Rio, D. Anti-estrogenic activity of a human resveratrol metabolite. Nutrition, metabolism, and cardiovascular diseases : NMCD 2013, 23, (11), 1086-92. Cerca con Google

125. Wu, J. M.; Hsieh, T. C.; Yang, C. J.; Olson, S. C. Resveratrol and its metabolites modulate cytokine-mediated induction of eotaxin-1 in human pulmonary artery endothelial cells. Annals of the New York Academy of Sciences 2013, 1290, 30-6. Cerca con Google

126. Polycarpou, E.; Meira, L. B.; Carrington, S.; Tyrrell, E.; Modjtahedi, H.; Carew, M. A. Resveratrol 3-O-D-glucuronide and resveratrol 4'-O-D-glucuronide inhibit colon cancer cell growth: evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest. Molecular nutrition & food research 2013, 57, (10), 1708-17. Cerca con Google

127. Ruotolo, R.; Calani, L.; Brighenti, F.; Crozier, A.; Ottonello, S.; Del Rio, D. Glucuronidation does not suppress the estrogenic activity of quercetin in yeast and human breast cancer cell model systems. Archives of biochemistry and biophysics 2014, 559, 62-7. Cerca con Google

128. Bresciani, L.; Calani, L.; Bocchi, L.; Delucchi, F.; Savi, M.; Ray, S.; Brighenti, F.; Stilli, D.; Del Rio, D. Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutrition, metabolism, and cardiovascular diseases : NMCD 2014, 24, (4), 408-15. Cerca con Google

129. Ladurner, A.; Schachner, D.; Schueller, K.; Pignitter, M.; Heiss, E. H.; Somoza, V.; Dirsch, V. M. Impact of trans-resveratrol-sulfates and -glucuronides on endothelial nitric oxide synthase activity, nitric oxide release and intracellular reactive oxygen species. Molecules (Basel, Switzerland) 2014, 19, (10), 16724-36. Cerca con Google

130. Maier-Salamon, A.; Bohmdorfer, M.; Riha, J.; Thalhammer, T.; Szekeres, T.; Jaeger, W. Interplay between metabolism and transport of resveratrol. Annals of the New York Academy of Sciences 2013, 1290, 98-106. Cerca con Google

131. Andreadi, C.; Britton, R. G.; Patel, K. R.; Brown, K. Resveratrol-sulfates provide an intracellular reservoir for generation of parent resveratrol, which induces autophagy in cancer cells. Autophagy 2014, 10, (3), 524-5. Cerca con Google

132. Scalbert, A.; Morand, C.; Manach, C.; Remesy, C. Absorption and metabolism of polyphenols in the gut and impact on health. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2002, 56, (6), 276-82. Cerca con Google

133. Scalbert, A.; Williamson, G. Dietary intake and bioavailability of polyphenols. The Journal of nutrition 2000, 130, (8S Suppl), 2073s-85s. Cerca con Google

134. Lampe, J. W. Is equol the key to the efficacy of soy foods? The American journal of clinical nutrition 2009, 89, (5), 1664s-1667s. Cerca con Google

135. Yuan, J. P.; Wang, J. H.; Liu, X. Metabolism of dietary soy isoflavones to equol by human intestinal microflora--implications for health. Molecular nutrition & food research 2007, 51, (7), 765-81. Cerca con Google

136. Jackson, R. L.; Greiwe, J. S.; Schwen, R. J. Emerging evidence of the health benefits of S-equol, an estrogen receptor beta agonist. Nutrition reviews 2011, 69, (8), 432-48. Cerca con Google

137. Shor, D.; Sathyapalan, T.; Atkin, S. L.; Thatcher, N. J. Does equol production determine soy endocrine effects? European journal of nutrition 2012, 51, (4), 389-98. Cerca con Google

138. Williamson, G.; Clifford, M. N. Colonic metabolites of berry polyphenols: the missing link to biological activity? The British journal of nutrition 2010, 104 Suppl 3, S48-66. Cerca con Google

139. Possemiers, S.; Bolca, S.; Verstraete, W.; Heyerick, A. The intestinal microbiome: a separate organ inside the body with the metabolic potential to influence the bioactivity of botanicals. Fitoterapia 2011, 82, (1), 53-66. Cerca con Google

140. Calani, L.; Dall'Asta, M.; Derlindati, E.; Scazzina, F.; Bruni, R.; Del Rio, D. Colonic metabolism of polyphenols from coffee, green tea, and hazelnut skins. Journal of clinical gastroenterology 2012, 46 Suppl, S95-9. Cerca con Google

141. Dall'Asta, M.; Calani, L.; Tedeschi, M.; Jechiu, L.; Brighenti, F.; Del Rio, D. Identification of microbial metabolites derived from in vitro fecal fermentation of different polyphenolic food sources. Nutrition (Burbank, Los Angeles County, Calif.) 2012, 28, (2), 197-203. Cerca con Google

142. Rodriguez-Mateos, A.; Vauzour, D.; Krueger, C. G.; Shanmuganayagam, D.; Reed, J.; Calani, L.; Mena, P.; Del Rio, D.; Crozier, A. Bioavailability, bioactivity and impact on health of dietary flavonoids and related compounds: an update. Archives of toxicology 2014, 88, (10), 1803-53. Cerca con Google

143. Forester, S. C.; Waterhouse, A. L. Metabolites are key to understanding health effects of wine polyphenolics. The Journal of nutrition 2009, 139, (9), 1824s-31s. Cerca con Google

144. Del Rio, D.; Costa, L. G.; Lean, M. E.; Crozier, A. Polyphenols and health: what compounds are involved? Nutrition, metabolism, and cardiovascular diseases : NMCD 2010, 20, (1), 1-6. Cerca con Google

145. Del Rio, D.; Calani, L.; Cordero, C.; Salvatore, S.; Pellegrini, N.; Brighenti, F. Bioavailability and catabolism of green tea flavan-3-ols in humans. Nutrition (Burbank, Los Angeles County, Calif.) 2010, 26, (11-12), 1110-6. Cerca con Google

146. Del Rio, D.; Borges, G.; Crozier, A. Berry flavonoids and phenolics: bioavailability and evidence of protective effects. The British journal of nutrition 2010, 104 Suppl 3, S67-90. Cerca con Google

147. Crozier, A.; Del Rio, D.; Clifford, M. N. Bioavailability of dietary flavonoids and phenolic compounds. Molecular aspects of medicine 2010, 31, (6), 446-67. Cerca con Google

148. Monagas, M.; Urpi-Sarda, M.; Sanchez-Patan, F.; Llorach, R.; Garrido, I.; Gomez-Cordoves, C.; Andres-Lacueva, C.; Bartolome, B. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites. Food & function 2010, 1, (3), 233-53. Cerca con Google

149. Russell, W.; Duthie, G. Plant secondary metabolites and gut health: the case for phenolic acids. The Proceedings of the Nutrition Society 2011, 70, (3), 389-96. Cerca con Google

150. Verzelloni, E.; Pellacani, C.; Tagliazucchi, D.; Tagliaferri, S.; Calani, L.; Costa, L. G.; Brighenti, F.; Borges, G.; Crozier, A.; Conte, A.; Del Rio, D. Antiglycative and neuroprotective activity of colon-derived polyphenol catabolites. Molecular nutrition & food research 2011, 55 Suppl 1, S35-43. Cerca con Google

151. Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J. P.; Tognolini, M.; Borges, G.; Crozier, A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxidants & redox signaling 2013, 18, (14), 1818-92. Cerca con Google

152. Clifford, M. N.; van der Hooft, J. J.; Crozier, A. Human studies on the absorption, distribution, metabolism, and excretion of tea polyphenols. The American journal of clinical nutrition 2013, 98, (6 Suppl), 1619s-1630s. Cerca con Google

153. Fernandez-Millan, E.; Ramos, S.; Alvarez, C.; Bravo, L.; Goya, L.; Martin, M. A. Microbial phenolic metabolites improve glucose-stimulated insulin secretion and protect pancreatic beta cells against tert-butyl hydroperoxide-induced toxicity via ERKs and PKC pathways. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2014, 66, 245-53. Cerca con Google

154. Pereira-Caro, G.; Borges, G.; van der Hooft, J.; Clifford, M. N.; Del Rio, D.; Lean, M. E.; Roberts, S. A.; Kellerhals, M. B.; Crozier, A. Orange juice (poly)phenols are highly bioavailable in humans. The American journal of clinical nutrition 2014, 100, (5), 1378-84. Cerca con Google

155. Escudero-Lopez, B.; Calani, L.; Fernandez-Pachon, M. S.; Ortega, A.; Brighenti, F.; Crozier, A.; Del Rio, D. Absorption, metabolism, and excretion of fermented orange juice (poly)phenols in rats. BioFactors (Oxford, England) 2014, 40, (3), 327-35. Cerca con Google

156. Visioli, F. The resveratrol fiasco. Pharmacological research : the official journal of the Italian Pharmacological Society 2014, 90, 87. Cerca con Google

157. Amri, A.; Chaumeil, J. C.; Sfar, S.; Charrueau, C. Administration of resveratrol: What formulation solutions to bioavailability limitations? Journal of controlled release : official journal of the Controlled Release Society 2012, 158, (2), 182-93. Cerca con Google

158. Smoliga, J. M.; Blanchard, O. Enhancing the delivery of resveratrol in humans: if low bioavailability is the problem, what is the solution? Molecules (Basel, Switzerland) 2014, 19, (11), 17154-72. Cerca con Google

159. Augustin, M. A.; Sanguansri, L.; Lockett, T. Nano- and micro-encapsulated systems for enhancing the delivery of resveratrol. Annals of the New York Academy of Sciences 2013, 1290, 107-12. Cerca con Google

160. Pangeni, R.; Sahni, J. K.; Ali, J.; Sharma, S.; Baboota, S. Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert opinion on drug delivery 2014, 11, (8), 1285-98. Cerca con Google

161. Biasutto, L.; Mattarei, A.; Sassi, N.; Azzolini, M.; Romio, M.; Paradisi, C.; Zoratti, M. Improving the efficacy of plant polyphenols. Anti-cancer agents in medicinal chemistry 2014, 14, (10), 1332-42. Cerca con Google

162. Biasutto, L.; Zoratti, M. Prodrugs of quercetin and resveratrol: a strategy under development. Current drug metabolism 2014, 15, (1), 77-95. Cerca con Google

Solo per lo Staff dell Archivio: Modifica questo record